Inhaled Beclomethasone After Community-Acquired Respiratory Viral Infection in Lung Transplant Recipients
A Randomized Placebo Controlled Trial of Inhaled Beclomethasone After Community-acquired Respiratory Viral Infection in Lung Transplant Recipients
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110
- Washington University School of Medicine
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Adult (≥ 18 years old)
- Single, bilateral, or heart-lung transplant recipient
- Confirmed infection with a community-acquired respiratory virus including: adenovirus, coronavirus, influenza A or B, respiratory syncytial virus (RSV), parainfluenza virus (PiV), human metapneumovirus (hMPV), and rhinovirus
- At least 6 months post-transplant, with completion of 6 month bronchoscopy if indicated
- Able and willing to give written informed consent and comply with study procedures (e.g. testing, treatment)
Exclusion Criteria:
- BOS Stage 3
- Requirement for mechanical ventilation at study entry
- Use of inhaled steroids at the time of CARV infection
- Any condition that in the investigator's opinion would preclude the patient's participation in a clinical trial
- Lack of available spirometric data to establish a baseline forced expiratory volume in 1 second and/or forced vital capacity
- Pregnancy
- Current participation in another interventional clinical trial
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Inhaled beclomethasone
Inhaled beclomethasone 320 mcg twice daily for 180 days.
|
Inhaled steroid that may decrease airway inflammation and the risk of chronic rejection
|
|
Placebo Comparator: Placebo
Inhaled placebo twice daily for 180 days.
|
Placebo will serve as a control treatment
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Death
Time Frame: 180 days
|
180 days
|
|
Number of Participants Free From New or Progressive Chronic Lung Allograft Dysfunction
Time Frame: 180 days
|
180 days
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Acute Rejection
Time Frame: 180 days
|
180 days
|
|
Lymphocytic Bronchiolitis
Time Frame: 180 days
|
180 days
|
|
Donor-specific Antibodies
Time Frame: 180 days
|
180 days
|
|
Chronic Lung Allograft Dysfunction
Time Frame: 180 days
|
180 days
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Ramsey Hachem, MD, Washington University School of Medicine
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- WUIBCARV1-201404080
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.